In a 79-year-old male with gynecomastia, normal hormonal workup, and no suspicious findings on mammography and breast ultrasound, could his medications—aspirin, cilostazol, furosemide (Lasix), rosuvastatin, and valsartan—be causing the gynecomastia?

Medication-Induced Gynecomastia Assessment

Among this patient's medications, spironolactone is not listed, but furosemide (Lasix) and rosuvastatin are both associated with gynecomastia, though the evidence is stronger for rosuvastatin. The other medications (aspirin, cilostazol, valsartan) have minimal to no documented association with gynecomastia.

Medication-Specific Analysis

Furosemide (Lasix) - Possible Culprit

Furosemide has documented associations with gynecomastia, though the mechanism and frequency are less well-characterized than with spironolactone. One case report demonstrated gynecomastia when furosemide was co-administered with digoxin 1. However, furosemide alone is a recognized but uncommon cause of gynecomastia 2. The mechanism may involve hormonal imbalance through effects on the testosterone-to-estradiol ratio.

Rosuvastatin - More Likely Culprit

Rosuvastatin has stronger evidence for causing gynecomastia:

• Case reports specifically document rosuvastatin-induced gynecomastia 3, with resolution upon switching to alternative statins
• A large case-control study (6,147 cases) found statins increased gynecomastia risk with adjusted rate ratios of 1.19 for current use, 1.38 for recent use, and 1.20 for past use 4
• Italian pharmacovigilance data identified rosuvastatin among the statins most frequently associated with gynecomastia 5
• A comprehensive FDA adverse event database analysis identified statins as associated with gynecomastia 6
• The mechanism involves inhibition of HMG-CoA reductase, which suppresses cholesterol synthesis and subsequently affects steroidogenesis, potentially reducing testosterone production 3, 7

The more potent statins (rosuvastatin, atorvastatin) appear to have higher association rates 5, likely due to their stronger inhibition of steroidogenesis.

Other Medications - Unlikely Contributors

• Aspirin: No documented association with gynecomastia
• Cilostazol: No documented association with gynecomastia. Recent pharmacokinetic studies show no significant interaction with rosuvastatin 8
• Valsartan: ARBs are not typically associated with gynecomastia (unlike spironolactone, which is a mineralocorticoid receptor antagonist)

Clinical Approach

Diagnostic Confirmation

Your patient's workup is appropriate:

• Normal hormonal evaluation rules out endocrine causes
• Negative mammography and ultrasound exclude malignancy (important given his age, as male breast cancer median age is 63 years) 2
• Gynecomastia is not a risk factor for male breast cancer 2, though 50% of men with breast cancer may have coexisting gynecomastia 2

Management Strategy

Consider a therapeutic trial with medication modification:

1. First-line approach: Switch rosuvastatin to a different statin with lower gynecomastia risk

   • Pravastatin or fluvastatin have fewer reports of gynecomastia
   • One case report showed resolution within 1 month after switching from rosuvastatin to atorvastatin 3, though atorvastatin also carries risk 7
   • Monitor for symptom resolution over 4-8 weeks

2. Alternative approach: Temporarily discontinue rosuvastatin

   • If gynecomastia resolves, this confirms the diagnosis
   • Can then trial alternative lipid-lowering therapy

3. Consider furosemide contribution: If symptoms persist after addressing rosuvastatin, evaluate whether furosemide can be reduced or switched to an alternative diuretic without gynecomastia risk

Important Caveats

• Do not discontinue cardiovascular medications without careful risk-benefit assessment - this 79-year-old patient likely has significant cardiovascular disease given his medication regimen
• The combination of cilostazol and rosuvastatin has been studied and shows no significant pharmacokinetic interaction 8
• Age is a risk factor: Physiologic gynecomastia occurs with aging 2, but medication-induced causes should still be addressed given the temporal relationship and patient discomfort
• If symptoms are mild and not bothersome, observation may be appropriate given the cardiovascular benefits of statin therapy

Monitoring Parameters

• Reassess breast symptoms at 4-8 weeks after any medication change
• Continue cardiovascular risk management
• Document symptom resolution or persistence to guide further management